BEAMSTART Logo

HomeNews

RNA Drug Developer Targets Fresh Funding Channel

Benzinga LogoBenzinga13h ago

RNA Drug Developer Targets Fresh Funding Channel - Benzinga

Quick Summary:

The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in gene-targeted therapy, Ribo Life has six siRNA candidate drugs undergoing clinical trials

It previously raised 1.8 billion yuan from industry investors and also derives income from licensing partnerships They have been hailed as a new frontier in pharmacology: chemically synthesized drugs based on nucleic acids in the human genome.

RNA acts as a bridge connecting genes and proteins, while chemically modified oligonucleotides help to create drugs with prolonged potency and wide uses. With these advantages, nucleotide medicines have been tipped to become the third major new class of innovative remedies after small molecule and antibody drugs.

More Pictures

RNA Drug Developer Targets Fresh Funding Channel - Benzinga (Picture 1)

or

Article Details

Author / Journalist: Bamboo Works

Category: InvestingBusiness

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-05-08 @ 12:19:07 (13 hours ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 1026 words

Reading Time: 6 minutes read

Sentences: 40 lines

Sentence Length: 26 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 28494307

View Article Analysis

About Benzinga

Benzinga Logo

Main Topics: InvestingBusiness

Official Website: benzinga.com

Update Frequency: 4 posts per day

Year Established: 2010

Headquarters: United States

News Last Updated: 11 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "RNA Drug Developer Targets Fresh Funding Channel" has 1026 words across 40 sentences, which will take approximately 5 - 9 minutes for the average person to read.

Which news outlet covered this story?

The story "RNA Drug Developer Targets Fresh Funding Channel" was covered 13 hours ago by Benzinga, a news publisher based in United States.

How trustworthy is 'Benzinga' news outlet?

Benzinga is a fully independent (privately-owned) news outlet established in 2010 that covers mostly investing and business news.

The outlet is headquartered in United States and publishes an average of 4 news stories per day.

It's most recent story was published 11 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #28494307
  • URL: https://goldengate-staging18.beamstart.com/news/rna-drug-developer-targets-fresh-17467121896024

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

Our Company

© Copyright 2025 BEAMSTART. All Rights Reserved.